View Older Stories View More Recent Stories
-
Erste Group Downgrades Eli Lilly (LLY) to Hold
-
Amgen (AMGN) Falls 8% Following Obesity Data, Rivals Lilly (LLY), Novo Nordisk (NVO) Gain 4%
-
Eli Lilly & Co. (LLY) and Novo Nordisk (NVO) gain on Biden's GLP-1 proposal
-
Eli Lilly & Co. (LLY) call put ratio 1.9 calls to 1 put as share price up before the bell
-
TD Cowen analyst says FDA decision on this popular weight-loss drug could signal market shift
-
Eli Lilly & Co. (LLY) Announces Board Changes
-
Eli Lilly & Co. (LLY) Announces Board Changes
-
JPM just added these stocks to its Analyst Focus List - giving one 148% upside
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Moderna (MRNA), Others on Watch Following Report Trump Expected to Select Robert F. Kennedy Jr. to lead HHS
-
Citi is 'aggressively' buying selloff in this pharma stock
-
Eli Lilly (LLY) PT Lowered to $1,010 at BMO Capital
-
Eli Lilly (LLY) PT Lowered to $1,029 at Truist Securities
-
Eli Lilly & Co. (LLY) Misses Q3 EPS by 27c; guides below consensus
-
Eli Lilly & Co. (LLY) Reports Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
-
Eli Lilly & Co. (LLY) November 1 weekly option implied volatility into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put into quarter results
-
Eli Lilly & Co. (LLY) Declares $1.30 Quarterly Dividend; 0.6% Yield
-
Eli Lilly's (LLY) mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease
-
Eli Lilly & Co. (LLY) Reports EBGLYSS demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupil
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
This pharma stock could deliver a beat and raise quarter, according to Wells Fargo
-
Hims & Hers (HIMS) Climbs as FDA to Reconsider Decision Barring Compounded Versions of Eli Lilly (LLY) Weight Loss Drug
-
Eli Lilly & Co. (LLY) reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Raised to $1,033 at Truist Securities
-
Obesity Drug Coverage Could Boost Spending By $35B Through 2034: CBO
-
TD Cowen Reiterates Buy Rating on Eli Lilly (LLY)
-
Attorney General Ken Paxton Sues Big Pharma Drug Manufacturers and Pharmacy Benefit Managers for Conspiracy That Increased Insulin Prices by 1,000%
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY) After FDA Says Tirzepatide is No Longer on Shortage Lists
-
Hims & Hers Health (HIMS) Falls 8% as Shortage of Lilly's (LLY) Weight-Loss Drug Ends
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
Deutsche Bank Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) announces $4.5B investment to create the Lilly Medicine Foundry
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
FDA Oks Eli Lilly's (LLY) Selpercatinib For Medullary Thyroid Cancer - Bloomberg
-
Eli Lilly & Co. (LLY) reports new data showing EBGLYSS provided sustained disease control for up to three years in more than 80% of adults and adolescents
-
Eli Lilly & Co. (LLY) option IV flat
-
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
-
Deutsche Bank on Eli Lilly (LLY): 'CB-1 Appetite Suppression Looks Underwhelming'
-
Eli Lilly (LLY) call put ratio 2.1 calls to 1 put as share price up 1.9%
-
Eli Lilly & Co. (LLY) gains after Novo Nordisk's monlunabant obesity data
-
Eli Lilly & Co. (LLY) option IV near lower end of range
-
JPMorgan refreshed its U.S. Analyst Focus List and added these four names
-
Eli Lilly & Co. (LLY) Announces FDA Approval of EBGLYSS for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
-
Citi restarts coverage of Eli Lilly with Buy rating on increased tirzepatide forecasts
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Citi Resumes Eli Lilly (LLY) at Buy
-
Eli Lilly & Co. (LLY) Announces $1.8B investment in manufacturing in Ireland

